March 09, 2015
The directors of Ariad Pharmaceuticals Inc. shut down a shareholder derivative suit alleging Ariad's leadership hid problems with a leukemia drug it eventually pulled from the market, sending the company to the brink of financial disaster, according to an order filed Monday in Massachusetts federal court.